<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Allergy Asthma Clin Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Allergy Asthma Clin Immunol</journal-id><journal-title-group><journal-title>Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology</journal-title></journal-title-group><issn pub-type="ppub">1710-1484</issn><issn pub-type="epub">1710-1492</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4126061</article-id><article-id pub-id-type="publisher-id">1710-1492-10-S1-A68</article-id><article-id pub-id-type="doi">10.1186/1710-1492-10-S1-A68</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>Double blind randomized crossover trial of PF-03654764+fexofenadine in the environmental exposure unit (EEU)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>North</surname><given-names>Michelle L</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Walker</surname><given-names>Terry</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Steacy</surname><given-names>Lisa M</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Hobsbawn</surname><given-names>Barnaby G</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Allan</surname><given-names>Richard J</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Hackman</surname><given-names>Frances</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Sun</surname><given-names>Xiaoqun</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Day</surname><given-names>Andrew G</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Ellis</surname><given-names>Anne K</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I5">5</xref></contrib></contrib-group><aff id="I1"><label>1</label>Department of Biomedical and Molecular Sciences, Queen&#x02019;s University, Kingston, Ontario, Canada, K7L 2V5</aff><aff id="I2"><label>2</label>Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada, K7L 2V7</aff><aff id="I3"><label>3</label>Pfizer Ltd., Sandwich, Kent, CT13 9NJ, UK</aff><aff id="I4"><label>4</label>Clinical Research Centre, Kingston General Hospital, Kingston, Ontario, Canada, K7L 2V7</aff><aff id="I5"><label>5</label>Division of Allergy and Immunology, Department of Medicine, Queen&#x02019;s University, Kingston, Ontario, Canada, K7L 2V7</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>3</day><month>3</month><year>2014</year></pub-date><volume>10</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2013</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by the CSACI and AllerGen.</named-content></supplement><fpage>A68</fpage><lpage>A68</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 North et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>North et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.aacijournal.com/content/10/S1/A68"/><conference><conf-date>3-6 October 2013</conf-date><conf-name>Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2013</conf-name><conf-loc>Toronto, Canada</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>Oral histamine receptor&#x02013;1 antagonists, such as fexofenadine, offer suboptimal relief of allergic rhinitis-associated nasal congestion. Combinations with oral sympathomimetics, such as pseudoephedrine, relieve congestion but produce side effects. Histamine receptor-3 antagonists, such as PF-03654764, reduce congestion in animals and have been proposed as novel therapeutics. Previous nasal allergen challenge studies of similar H1+H3 receptor antagonist combinations demonstrated reduced congestion. Herein we employ the Environmental Exposure Unit (EEU) to conduct the first randomized controlled trial of PF-03654764 in allergic rhinitis. The primary objective was to compare the effect of PF-03654764+fexofenadine to pseudoephedrine+fexofenadine on the subjective measures of congestion and Total Nasal Symptom Score (TNSS). The objective of post-hoc analyses were to compare all treatments to placebo and determine the onset of action (OA).</p></sec><sec sec-type="methods"><title>Methods</title><p>64 participants were randomized in a double-blind, placebo-controlled 4-period crossover study. Participants were exposed to ragweed pollen for 6 hours post-dose in the EEU.</p></sec><sec sec-type="results"><title>Results</title><p>PF-03654764+fexofenadine was not superior to pseudoephedrine+fexofenadine. In post-hoc analyses, PF-03654764+fexofenadine significantly reduced TNSS, relative to placebo, and OA was 60 minutes. Pseudoephedrine+fexofenadine significantly reduced congestion and TNSS, relative to placebo, with OA of 60 and 30 minutes, respectively. All PF-03654764-treated groups experienced an elevated incidence of adverse events.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>PF-03654764+fexofenadine failed to provide superior relief of allergic rhinitis-associated nasal symptoms upon exposure to ragweed pollen compared to fexofenadine+pseudoephedrine. However, PF-03654764+fexofenadine improved TNSS compared to placebo. Side effects were not insignificant.</p></sec></body></article>